SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Healing & RepairResearch peptide

TB-500

aka Thymosin Beta-4 fragment

A synthetic fragment of thymosin beta-4 studied for systemic tissue regeneration, vascular growth, and wound closure.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

TB-500 is a synthetic peptide based on a region of the naturally occurring thymosin beta-4 protein, which regulates cell migration, blood-vessel formation, and tissue repair.

Source
  • Synthesized in research laboratories
Forms
  • Subcutaneous or intramuscular injection

Mechanism of action

Binds and sequesters actin monomers, promoting cell migration, new blood-vessel formation, and reduction of inflammation at injury sites.

Pathways
  • · Actin regulation (G-actin sequestration)
  • · Angiogenesis
  • · Stem-cell migration to injury sites

How it acts on the body

Thymosin beta-4, the parent molecule of TB-500, is the most abundant intracellular G-actin-binding protein in the body. By holding actin monomers in a 'ready' state, it lets cells rapidly reorganize their cytoskeleton — which is exactly what is needed when fibroblasts, endothelial cells, and stem cells migrate into a wound.

When injected, the fragment behaves systemically: it concentrates at sites of inflammation, where damaged tissue releases chemotactic cues. There it accelerates progenitor-cell recruitment and amplifies VEGF-driven capillary growth. The effect is not hormonal in the classical sense — there's no endocrine axis activation — but it does shift the body into a 'repair-favoring' inflammatory profile, increasing anti-inflammatory cytokines like IL-10 and tempering TNF-α.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Inflammatory cytokines (TNF-α, IL-6)Decreases
Dampens pro-inflammatory cytokine output at injury sites in animal models.
IL-10 (anti-inflammatory)Increases
Shifts cytokine balance toward resolution and repair.
VEGFIncreases
Indirectly raises local VEGF expression, supporting new blood-vessel growth.
Sex hormones / GH axisStabilizes
No meaningful direct effect on testosterone, estrogen, or GH/IGF-1 reported.

Effects on the body

Increases
Cell migration toward injury
Supports
Wound and tendon healing in animals
Decreases
Local inflammation

Organ system effects

Skeletal Muscle

Speeds healing of muscle and tendon injuries in equine and rodent studies.

Cardiovascular

Animal data suggest cardiac repair after ischemic injury by mobilizing epicardial progenitor cells.

Skin

Promotes wound closure and reduces scarring in animal wound models.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Used in veterinary practice for racehorse soft-tissue recovery
  • Anecdotal faster recovery from overuse injuries
  • May improve flexibility and range of motion post-injury

Potential side effects

Common
  • · Injection-site reaction
  • · Lethargy for 24–48 hours
Rare
  • · Headache
  • · Mild flu-like feeling
Serious
  • · Long-term safety in humans is unknown

Drug interactions

Immunosuppressants
Theoretical interference with immune-mediated healing pathways.
moderate

Pairing context

Often combined with
  • BPC-157
    Commonly paired for complementary repair effects in research protocols.
Avoid combining with
  • Active cancer therapy
    Angiogenic and migratory signals may be inappropriate during treatment.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.